Brief: Neurotech International Seeks Trading Halt
15/03/2023 24:25
March 15 (Reuters) - Neurotech International Ltd
NTI.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON FINAL 54 WEEK
EFFICACY DATA FROM PHASE I/II CLINICAL TRIAL
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON DATA FROM PHASE
I/II
CLINICAL TRIAL IN AUTISM SPECTRUM DISORDER
Source text for Eikon: ID:nASX5Mvjd4
Further company coverage: NTI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt